,CHAPTER LIST Pancreas and Glucose Homeostasis
Chapter: 32 Pharmacology of Bone Mineral
Chapter: 1 Drug–Receptor Interactions Homeostasis
Chapter: 2 Pharmacodynamics Chapter: 33 Principles of Antimicrobial and
Chapter: 3 Pharmacokinetics Antineoplastic Pharmacology
Chapter: 4 Drug Metabolism Chapter: 34 Pharmacology of Bacterial
Chapter: 5 Drug Transporters Infections: DNA Replication, Transcription, and
Chapter: 6 Drug Toxicity Translation
Chapter: 7 Pharmacogenomics Chapter: 35 Pharmacology of Bacterial and
Chapter: 8 Principles of Cellular Excitability Mycobacterial Infections: Cell Wall Synthesis
and Electrochemical Transmission Chapter: 36 Pharmacology of Fungal Infections
Chapter: 9 Principles of Nervous System Chapter: 37 Pharmacology of Parasitic
Physiology and Pharmacology Infections
Chapter: 10 Cholinergic Pharmacology Chapter: 38 Pharmacology of Viral Infections
Chapter: 11 Adrenergic Pharmacology Chapter: 39 Pharmacology of Cancer: Genome
Chapter: 12 Local Anesthetic Pharmacology Synthesis, Stability, and Maintenance
Chapter: 13 Pharmacology of GABAergic and Chapter: 40 Pharmacology of Cancer: Signal
Glutamatergic Neurotransmission Transduction
Chapter: 14 Pharmacology of Dopaminergic Chapter: 41 Principles of Combination
Neurotransmission Chemotherapy
Chapter: 15 Pharmacology of Serotonergic and Chapter: 42 Principles of Inflammation and the
Central Adrenergic Neurotransmission Immune System
Chapter: 16 Pharmacology of Abnormal Chapter: 43 Pharmacology of Eicosanoids
Electrical Neurotransmission in the Central Chapter: 44 Histamine Pharmacology
Nervous System Chapter: 45 Pharmacology of Hematopoiesis and
Chapter: 17 General Anesthetic Pharmacology Immunomodulation
Chapter: 18 Pharmacology of Analgesia Chapter: 46 Pharmacology of
Chapter: 19 Pharmacology of Drugs of Abuse Immunosuppression
Chapter: 20 Pharmacology of Cholesterol and Chapter: 47 Integrative Inflammation
Lipoprotein Metabolism Pharmacology: Peptic Ulcer Disease
Chapter: 21 Pharmacology of Volume Chapter: 48 Integrative Inflammation
Regulation Pharmacology: Asthma
Chapter: 22 Pharmacology of Vascular Tone Chapter: 49 Integrative Inflammation
Chapter: 23 Pharmacology of Hemostasis and Pharmacology: Gout
Thrombosis Chapter: 50 Environmental Toxicology
Chapter: 24 Pharmacology of Cardiac Rhythm Chapter: 51 Drug Discovery and Preclinical
Chapter: 25 Pharmacology of Cardiac Development
Contractility Chapter: 52 Clinical Drug Evaluation and
Chapter: 26 Integrative Cardiovascular Regulatory Approval
Pharmacology: Hypertension, Ischemic Heart Chapter: 53 Systematic Detection of Adverse
Disease, and Heart Failure Drug Events
Chapter: 27 Pharmacology of the Hypothalamus Chapter: 54 Protein Therapeutics
and Pituitary Gland Chapter: 55 Drug Delivery Modalities
Chapter: 28 Pharmacology of the Thyroid Gland
Chapter: 29 Pharmacology of the Adrenal
Cortex
Chapter: 30 Pharmacology of Reproduction
Chapter: 31 Pharmacology of the Endocrine
,Chapter 1: Drug–Receptor Interactions
Context: Introduces the molecular basis of drug action. Discusses drug–receptor theory,
agonists vs antagonists, dose–response relationships, receptor selectivity, and signal
transduction.
Clinical relevance: Understanding how drugs interact with receptors is critical for
predicting therapeutic and adverse effects.
Questions
1. A patient is given a competitive antagonist for the β1-adrenergic receptor. Which of the
following best describes the expected effect on the dose–response curve of a β1 agonist?
A) Decreased maximal response without changing EC50
B) Rightward shift of the curve without changing maximal response
C) Leftward shift of the curve
D) No change in the curve
Answer: B
Rationale: Competitive antagonists bind reversibly to the same site as the agonist,
requiring higher agonist concentration to achieve the same response. Maximal response
can still be achieved.
Key words: competitive antagonist, β1-adrenergic receptor, dose–response curve, EC50
2. Which type of receptor interaction is most likely responsible for the prolonged effect of a
drug after it has been cleared from plasma?
A) Reversible competitive binding
B) Covalent irreversible binding
C) Allosteric modulation
D) Non-specific binding
Answer: B
Rationale: Irreversible binding forms covalent bonds with the receptor, causing prolonged
effects even after plasma drug levels fall.
Key words: irreversible antagonist, covalent binding, prolonged drug effect
3. A partial agonist at a receptor:
A) Produces maximal response regardless of dose
B) Competes with a full agonist and reduces maximal effect
C) Has no effect unless co-administered with an antagonist
D) Always acts as a full agonist in vivo
Answer: B
Rationale: Partial agonists produce submaximal responses and can compete with full
,agonists, reducing maximal effect if both are present.
Key words: partial agonist, receptor occupancy, submaximal response, competitive
inhibition
4. Tachyphylaxis to a drug is most often due to:
A) Increased receptor synthesis
B) Receptor desensitization or down-regulation
C) Increased drug metabolism
D) Enhanced signal transduction
Answer: B
Rationale: Repeated drug exposure can cause receptor phosphorylation, internalization, or
down-regulation, reducing responsiveness.
Key words: tachyphylaxis, desensitization, receptor down-regulation, chronic exposure
5. The EC50 of a drug represents:
A) The maximum effect achievable
B) The dose producing 50% of maximal effect
C) The dose producing toxic effects in 50% of patients
D) The plasma concentration after 50 minutes
Answer: B
Rationale: EC50 is the effective concentration at which 50% of the maximal effect is
observed, reflecting potency.
Key words: EC50, potency, dose–response, pharmacodynamics
6. A drug has high receptor selectivity. Which of the following is true?
A) It binds multiple receptor types equally
B) It is more likely to cause off-target effects
C) It preferentially binds a specific receptor subtype
D) It has low efficacy at all receptors
Answer: C
Rationale: High selectivity means preferential binding to a particular receptor subtype,
reducing off-target effects.
Key words: receptor selectivity, specificity, off-target effects, binding affinity
7. Which mechanism explains why a noncompetitive antagonist reduces maximal
response?
A) Reversible competition at the active site
B) Covalent modification or allosteric binding
C) Increasing agonist concentration
D) Enhancing receptor expression
,Answer: B
Rationale: Noncompetitive antagonists reduce maximal response by binding irreversibly or
allosterically, preventing full receptor activation regardless of agonist concentration.
Key words: noncompetitive antagonist, allosteric inhibition, maximal response
8. Which receptor type mediates rapid responses via ion channels?
A) G protein–coupled receptors
B) Ligand-gated ion channels
C) Tyrosine kinase receptors
D) Nuclear receptors
Answer: B
Rationale: Ligand-gated ion channels allow immediate changes in ion flux, producing rapid
effects.
Key words: ligand-gated ion channels, fast signaling, neurotransmission
9. Which of the following best explains the effect of an allosteric modulator?
A) It binds the agonist binding site and competes directly
B) It alters receptor conformation to enhance or inhibit response
C) It degrades the receptor
D) It activates the receptor independent of agonist
Answer: B
Rationale: Allosteric modulators bind at a site distinct from the agonist binding site and
modulate receptor activity positively or negatively.
Key words: allosteric modulation, receptor conformation, positive/negative modulation
10. A patient has a genetic variant causing fewer functional receptors. What effect would
this have on a full agonist?
A) EC50 increases, maximal response unchanged
B) EC50 decreases, maximal response increases
C) Maximal response decreases, EC50 unchanged
D) No change in response
Answer: C
Rationale: Reduced receptor number decreases maximal achievable response; potency
(EC50) may remain unchanged if remaining receptors respond normally.
Key words: receptor density, genetic polymorphism, maximal effect, full agonist
11. Spare receptors in a tissue imply that:
A) Full response requires all receptors to be occupied
B) Maximal response can be achieved without full receptor occupancy
,C) Receptor number limits efficacy
D) Antagonists have no effect
Answer: B
Rationale: Spare receptors allow maximal effect at less than 100% occupancy, influencing
sensitivity and drug potency.
Key words: spare receptors, receptor occupancy, efficacy, pharmacodynamics
12. Which feature differentiates agonists from antagonists?
A) Only agonists bind receptors
B) Only agonists activate receptor signaling
C) Antagonists increase signal transduction
D) Both agonists and antagonists always elicit a maximal response
Answer: B
Rationale: Agonists bind and activate receptors to produce a response; antagonists block
activation without producing intrinsic effect.
Key words: agonist, antagonist, receptor activation, intrinsic activity
13. In the presence of a competitive antagonist, the concentration of agonist needed to
produce 50% of maximal effect will:
A) Decrease
B) Increase
C) Remain the same
D) Become zero
Answer: B
Rationale: Competitive antagonists require higher agonist concentrations to achieve same
response; EC50 shifts rightward.
Key words: competitive antagonist, EC50 shift, pharmacodynamics
14. Which receptor type regulates gene transcription?
A) Ionotropic receptors
B) Nuclear receptors
C) G protein–coupled receptors
D) Enzyme-linked receptors
Answer: B
Rationale: Nuclear receptors bind ligands, translocate to the nucleus, and regulate
transcription, producing slow but long-lasting effects.
Key words: nuclear receptors, transcription regulation, steroid hormones
, 15. Drug efficacy is defined as:
A) The dose producing half-maximal effect
B) The maximal effect a drug can produce
C) The drug’s safety margin
D) The time to peak plasma concentration
Answer: B
Rationale: Efficacy reflects the maximum response achievable with a drug, independent of
dose.
Key words: efficacy, maximal effect, pharmacodynamics
16. Which concept explains why some antagonists cannot be overcome by increasing
agonist concentration?
A) Competitive inhibition
B) Noncompetitive inhibition
C) Spare receptors
D) Dose–response relationship
Answer: B
Rationale: Noncompetitive antagonists reduce maximal response regardless of agonist
concentration because they bind irreversibly or allosterically.
Key words: noncompetitive antagonist, irreversibility, maximal response
17. A drug shows a steep dose–response curve. Which statement is correct?
A) Small dose changes produce large changes in effect
B) High doses are required for any effect
C) Maximal effect is unattainable
D) The drug is weakly potent
Answer: A
Rationale: Steep curves indicate high sensitivity; small dose changes lead to large
pharmacologic effects.
Key words: dose–response curve, slope, sensitivity, pharmacodynamics
18. Biased agonism refers to:
A) Activation of only one downstream signaling pathway by the receptor
B) Inability to bind the receptor
C) Receptor internalization without activation
D) Competitive antagonism
Answer: A
Rationale: Biased agonists selectively activate specific signaling cascades, producing
pathway-specific effects.
Key words: biased agonism, selective signaling, receptor pharmacology
Chapter: 32 Pharmacology of Bone Mineral
Chapter: 1 Drug–Receptor Interactions Homeostasis
Chapter: 2 Pharmacodynamics Chapter: 33 Principles of Antimicrobial and
Chapter: 3 Pharmacokinetics Antineoplastic Pharmacology
Chapter: 4 Drug Metabolism Chapter: 34 Pharmacology of Bacterial
Chapter: 5 Drug Transporters Infections: DNA Replication, Transcription, and
Chapter: 6 Drug Toxicity Translation
Chapter: 7 Pharmacogenomics Chapter: 35 Pharmacology of Bacterial and
Chapter: 8 Principles of Cellular Excitability Mycobacterial Infections: Cell Wall Synthesis
and Electrochemical Transmission Chapter: 36 Pharmacology of Fungal Infections
Chapter: 9 Principles of Nervous System Chapter: 37 Pharmacology of Parasitic
Physiology and Pharmacology Infections
Chapter: 10 Cholinergic Pharmacology Chapter: 38 Pharmacology of Viral Infections
Chapter: 11 Adrenergic Pharmacology Chapter: 39 Pharmacology of Cancer: Genome
Chapter: 12 Local Anesthetic Pharmacology Synthesis, Stability, and Maintenance
Chapter: 13 Pharmacology of GABAergic and Chapter: 40 Pharmacology of Cancer: Signal
Glutamatergic Neurotransmission Transduction
Chapter: 14 Pharmacology of Dopaminergic Chapter: 41 Principles of Combination
Neurotransmission Chemotherapy
Chapter: 15 Pharmacology of Serotonergic and Chapter: 42 Principles of Inflammation and the
Central Adrenergic Neurotransmission Immune System
Chapter: 16 Pharmacology of Abnormal Chapter: 43 Pharmacology of Eicosanoids
Electrical Neurotransmission in the Central Chapter: 44 Histamine Pharmacology
Nervous System Chapter: 45 Pharmacology of Hematopoiesis and
Chapter: 17 General Anesthetic Pharmacology Immunomodulation
Chapter: 18 Pharmacology of Analgesia Chapter: 46 Pharmacology of
Chapter: 19 Pharmacology of Drugs of Abuse Immunosuppression
Chapter: 20 Pharmacology of Cholesterol and Chapter: 47 Integrative Inflammation
Lipoprotein Metabolism Pharmacology: Peptic Ulcer Disease
Chapter: 21 Pharmacology of Volume Chapter: 48 Integrative Inflammation
Regulation Pharmacology: Asthma
Chapter: 22 Pharmacology of Vascular Tone Chapter: 49 Integrative Inflammation
Chapter: 23 Pharmacology of Hemostasis and Pharmacology: Gout
Thrombosis Chapter: 50 Environmental Toxicology
Chapter: 24 Pharmacology of Cardiac Rhythm Chapter: 51 Drug Discovery and Preclinical
Chapter: 25 Pharmacology of Cardiac Development
Contractility Chapter: 52 Clinical Drug Evaluation and
Chapter: 26 Integrative Cardiovascular Regulatory Approval
Pharmacology: Hypertension, Ischemic Heart Chapter: 53 Systematic Detection of Adverse
Disease, and Heart Failure Drug Events
Chapter: 27 Pharmacology of the Hypothalamus Chapter: 54 Protein Therapeutics
and Pituitary Gland Chapter: 55 Drug Delivery Modalities
Chapter: 28 Pharmacology of the Thyroid Gland
Chapter: 29 Pharmacology of the Adrenal
Cortex
Chapter: 30 Pharmacology of Reproduction
Chapter: 31 Pharmacology of the Endocrine
,Chapter 1: Drug–Receptor Interactions
Context: Introduces the molecular basis of drug action. Discusses drug–receptor theory,
agonists vs antagonists, dose–response relationships, receptor selectivity, and signal
transduction.
Clinical relevance: Understanding how drugs interact with receptors is critical for
predicting therapeutic and adverse effects.
Questions
1. A patient is given a competitive antagonist for the β1-adrenergic receptor. Which of the
following best describes the expected effect on the dose–response curve of a β1 agonist?
A) Decreased maximal response without changing EC50
B) Rightward shift of the curve without changing maximal response
C) Leftward shift of the curve
D) No change in the curve
Answer: B
Rationale: Competitive antagonists bind reversibly to the same site as the agonist,
requiring higher agonist concentration to achieve the same response. Maximal response
can still be achieved.
Key words: competitive antagonist, β1-adrenergic receptor, dose–response curve, EC50
2. Which type of receptor interaction is most likely responsible for the prolonged effect of a
drug after it has been cleared from plasma?
A) Reversible competitive binding
B) Covalent irreversible binding
C) Allosteric modulation
D) Non-specific binding
Answer: B
Rationale: Irreversible binding forms covalent bonds with the receptor, causing prolonged
effects even after plasma drug levels fall.
Key words: irreversible antagonist, covalent binding, prolonged drug effect
3. A partial agonist at a receptor:
A) Produces maximal response regardless of dose
B) Competes with a full agonist and reduces maximal effect
C) Has no effect unless co-administered with an antagonist
D) Always acts as a full agonist in vivo
Answer: B
Rationale: Partial agonists produce submaximal responses and can compete with full
,agonists, reducing maximal effect if both are present.
Key words: partial agonist, receptor occupancy, submaximal response, competitive
inhibition
4. Tachyphylaxis to a drug is most often due to:
A) Increased receptor synthesis
B) Receptor desensitization or down-regulation
C) Increased drug metabolism
D) Enhanced signal transduction
Answer: B
Rationale: Repeated drug exposure can cause receptor phosphorylation, internalization, or
down-regulation, reducing responsiveness.
Key words: tachyphylaxis, desensitization, receptor down-regulation, chronic exposure
5. The EC50 of a drug represents:
A) The maximum effect achievable
B) The dose producing 50% of maximal effect
C) The dose producing toxic effects in 50% of patients
D) The plasma concentration after 50 minutes
Answer: B
Rationale: EC50 is the effective concentration at which 50% of the maximal effect is
observed, reflecting potency.
Key words: EC50, potency, dose–response, pharmacodynamics
6. A drug has high receptor selectivity. Which of the following is true?
A) It binds multiple receptor types equally
B) It is more likely to cause off-target effects
C) It preferentially binds a specific receptor subtype
D) It has low efficacy at all receptors
Answer: C
Rationale: High selectivity means preferential binding to a particular receptor subtype,
reducing off-target effects.
Key words: receptor selectivity, specificity, off-target effects, binding affinity
7. Which mechanism explains why a noncompetitive antagonist reduces maximal
response?
A) Reversible competition at the active site
B) Covalent modification or allosteric binding
C) Increasing agonist concentration
D) Enhancing receptor expression
,Answer: B
Rationale: Noncompetitive antagonists reduce maximal response by binding irreversibly or
allosterically, preventing full receptor activation regardless of agonist concentration.
Key words: noncompetitive antagonist, allosteric inhibition, maximal response
8. Which receptor type mediates rapid responses via ion channels?
A) G protein–coupled receptors
B) Ligand-gated ion channels
C) Tyrosine kinase receptors
D) Nuclear receptors
Answer: B
Rationale: Ligand-gated ion channels allow immediate changes in ion flux, producing rapid
effects.
Key words: ligand-gated ion channels, fast signaling, neurotransmission
9. Which of the following best explains the effect of an allosteric modulator?
A) It binds the agonist binding site and competes directly
B) It alters receptor conformation to enhance or inhibit response
C) It degrades the receptor
D) It activates the receptor independent of agonist
Answer: B
Rationale: Allosteric modulators bind at a site distinct from the agonist binding site and
modulate receptor activity positively or negatively.
Key words: allosteric modulation, receptor conformation, positive/negative modulation
10. A patient has a genetic variant causing fewer functional receptors. What effect would
this have on a full agonist?
A) EC50 increases, maximal response unchanged
B) EC50 decreases, maximal response increases
C) Maximal response decreases, EC50 unchanged
D) No change in response
Answer: C
Rationale: Reduced receptor number decreases maximal achievable response; potency
(EC50) may remain unchanged if remaining receptors respond normally.
Key words: receptor density, genetic polymorphism, maximal effect, full agonist
11. Spare receptors in a tissue imply that:
A) Full response requires all receptors to be occupied
B) Maximal response can be achieved without full receptor occupancy
,C) Receptor number limits efficacy
D) Antagonists have no effect
Answer: B
Rationale: Spare receptors allow maximal effect at less than 100% occupancy, influencing
sensitivity and drug potency.
Key words: spare receptors, receptor occupancy, efficacy, pharmacodynamics
12. Which feature differentiates agonists from antagonists?
A) Only agonists bind receptors
B) Only agonists activate receptor signaling
C) Antagonists increase signal transduction
D) Both agonists and antagonists always elicit a maximal response
Answer: B
Rationale: Agonists bind and activate receptors to produce a response; antagonists block
activation without producing intrinsic effect.
Key words: agonist, antagonist, receptor activation, intrinsic activity
13. In the presence of a competitive antagonist, the concentration of agonist needed to
produce 50% of maximal effect will:
A) Decrease
B) Increase
C) Remain the same
D) Become zero
Answer: B
Rationale: Competitive antagonists require higher agonist concentrations to achieve same
response; EC50 shifts rightward.
Key words: competitive antagonist, EC50 shift, pharmacodynamics
14. Which receptor type regulates gene transcription?
A) Ionotropic receptors
B) Nuclear receptors
C) G protein–coupled receptors
D) Enzyme-linked receptors
Answer: B
Rationale: Nuclear receptors bind ligands, translocate to the nucleus, and regulate
transcription, producing slow but long-lasting effects.
Key words: nuclear receptors, transcription regulation, steroid hormones
, 15. Drug efficacy is defined as:
A) The dose producing half-maximal effect
B) The maximal effect a drug can produce
C) The drug’s safety margin
D) The time to peak plasma concentration
Answer: B
Rationale: Efficacy reflects the maximum response achievable with a drug, independent of
dose.
Key words: efficacy, maximal effect, pharmacodynamics
16. Which concept explains why some antagonists cannot be overcome by increasing
agonist concentration?
A) Competitive inhibition
B) Noncompetitive inhibition
C) Spare receptors
D) Dose–response relationship
Answer: B
Rationale: Noncompetitive antagonists reduce maximal response regardless of agonist
concentration because they bind irreversibly or allosterically.
Key words: noncompetitive antagonist, irreversibility, maximal response
17. A drug shows a steep dose–response curve. Which statement is correct?
A) Small dose changes produce large changes in effect
B) High doses are required for any effect
C) Maximal effect is unattainable
D) The drug is weakly potent
Answer: A
Rationale: Steep curves indicate high sensitivity; small dose changes lead to large
pharmacologic effects.
Key words: dose–response curve, slope, sensitivity, pharmacodynamics
18. Biased agonism refers to:
A) Activation of only one downstream signaling pathway by the receptor
B) Inability to bind the receptor
C) Receptor internalization without activation
D) Competitive antagonism
Answer: A
Rationale: Biased agonists selectively activate specific signaling cascades, producing
pathway-specific effects.
Key words: biased agonism, selective signaling, receptor pharmacology
